PROSPective Evaluation of Outcome After CatheTer Ablation in Atrial Fibrillation

Condition(s) studied

Investigational drug(s) / intervention(s)

atrial fibrillation catheter ablation: The ablation is performed under local anesthesia or general anesthesia. A transseptal puncture will be performed to access the left atrium. Pulmonary vein isolation will be performed as a first step. Additional lesions will be made at the discretion of the operators. Patients will receive anticoagulation for at least 3 months after the ablation. Treatment thereafter will be extended at the discretion of the treating physician.

Study summary

Atrial fibrillation ablation is the most common intervention performed worldwide. Up to 20 to 45% of patients show recurrence of AF within 12 month after catheter ablation, however its determinant are incompletely understood.

The aim of the PROSPECT-AF study is to assess the predictors of AF recurrence within the 3 years following ablation using clinical variables and innovative biomarkers in a prospective cohort of 750 patients undergoing atrial fibrillation catheter ablation.

The secondary aims are to assess the incidence of major adverse cardiovascular outcomes (MACE) and the incidence of major bleeding within the 3 years Wolfing catheter ablation.

Eligibility

Primary outcome measure(s)

• Incidence of atrial fibrillation recurrence. — At 3 years

Trial sites (1)

More University Hospital, Lille trials in France

Other trials for the same condition